SANDOZ-CALCITONIN NS LIQUID
Country: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
19-10-2010
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
CALCITONIN (SALMON SYNTHETIC)
Fáanlegur frá:
SANDOZ CANADA INCORPORATED
ATC númer:
H05BA01
INN (Alþjóðlegt nafn):
CALCITONIN (SALMON SYNTHETIC)
Skammtar:
200UNIT
Lyfjaform:
LIQUID
Samsetning:
CALCITONIN (SALMON SYNTHETIC) 200UNIT
Stjórnsýsluleið:
NASAL
Einingar í pakka:
200 U.I / SPRAY BOTTLE
Gerð lyfseðils:
Prescription
Lækningarsvæði:
PARATHYROID AND ANTIPARATHYROID AGENTS
Vörulýsing:
Active ingredient group (AIG) number: 0111011001; AHFS:
Leyfisstaða:
CANCELLED POST MARKET
Leyfisdagur:
2013-10-01
Vara einkenni
Sandoz Calcitonin NS
Page 1 of 35
PRODUCT MONOGRAPH
PR
SANDOZ CALCITONIN NS
Synthetic Calcitonin (Salmon)
Nasal Spray
200 IU/actuation
Bone Metabolism Regulator
Sandoz Canada Inc.
Date of Revision:
145 Jules-Léger
October 12, 2010
Boucherville, Quebec
J4B-7K8
Control number : 140901
Sandoz Calcitonin NS
Page 2 of 35
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..................................................3
SUMMARY PRODUCT
INFORMATION.............................................................................3
INDICATIONS AND CLINICAL
USE...................................................................................3
CONTRAINDICATIONS........................................................................................................4
WARNINGS AND
PRECAUTIONS......................................................................................4
ADVERSE
REACTIONS........................................................................................................5
DRUG
INTERACTIONS........................................................................................................10
DOSAGE AND
ADMINISTRATION....................................................................................11
OVERDOSAGE
……………………………………………………………………….........12
ACTION AND CLINICAL
PHARMACOLOGY..................................................................12
STORAGE AND
STABILITY...............................................................................................15
SPECIAL HANDLING
INSTRUCTIONS............................................................................15
DOSAGE FORMS, COMPOSITION AND
PACKAGING..................................................15
PART II: SCIENTIFIC
INFORMATION..........................................................................16
PHARMACEUTICAL
INFORMATION...............................................................................16
CLINICAL
TRIALS....................................................
Lestu allt skjalið
